Sawka Anna M, Ghai Sangeet, Rotstein Lorne, Irish Jonathan C, Pasternak Jesse D, Monteiro Eric, Chung Janet, Zahedi Afshan, Su Jie, Xu Wei, Jones Jennifer M, Gafni Amiram, Baxter Nancy N, Goldstein David P
Division of Endocrinology, University Health Network and University of Toronto, Toronto, Canada.
Joint Department of Medical Imaging, University Health Network-Mt Sinai Hospital-Women's College Hospital, University of Toronto, Toronto, Canada.
Thyroid. 2024 May;34(5):626-634. doi: 10.1089/thy.2023.0634. Epub 2024 Apr 8.
It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. We performed a prospective observational cohort study of Canadian patients with small (<2 cm) low-risk papillary thyroid cancer (PTC) who were offered the choice of active surveillance (AS) or surgery (Clinicaltrials.gov NCT03271892). Participants completed a questionnaire one year after their treatment decision. The primary intention-to-treat analysis compared the mean decision regret scale total score between patients who chose AS or surgery. A secondary analysis examined one-year decision regret score according to treatment status. Secondary outcomes included quality of life, mood, fear of disease progression, and body image perception. We adjusted for age, sex, and follow-up duration in linear regression analyses. The overall questionnaire response rate was 95.5% (191/200). The initial treatment choices of respondents were AS 79.1% (151/191) and surgery 20.9% (40/191). The mean age was 53 years (standard deviation [SD] 15 years) and 77% (147/191) were females. In the AS group, 7.3% (11/151) of patients crossed over to definitive treatment (two for disease progression) before the time of questionnaire completion. The mean level of decision regret did not differ significantly between patients who chose AS (mean 22.4, SD 13.9) or surgery (mean 20.9, SD 12.2) in crude ( = 0.730) or adjusted ( = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3-18.9], = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS ( = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.
了解癌症幸存者对其治疗决策和生活质量的看法非常重要。我们对加拿大患有小(<2厘米)低风险乳头状甲状腺癌(PTC)的患者进行了一项前瞻性观察队列研究,这些患者可以选择主动监测(AS)或手术(Clinicaltrials.gov NCT03271892)。参与者在做出治疗决定一年后完成了一份问卷。主要的意向性分析比较了选择AS或手术的患者之间的平均决策后悔量表总分。次要分析根据治疗状态检查了一年的决策后悔得分。次要结局包括生活质量、情绪、对疾病进展的恐惧和身体形象认知。我们在线性回归分析中对年龄、性别和随访时间进行了调整。问卷总体回复率为95.5%(191/200)。受访者最初的治疗选择是AS占79.1%(151/191),手术占20.9%(40/191)。平均年龄为53岁(标准差[SD]15岁),77%(147/191)为女性。在AS组中,7.3%(11/151)的患者在问卷完成前转为确定性治疗(2例因疾病进展)。在未调整(P = 0.730)或调整(P = 0.29)分析中,选择AS(平均22.4,SD 13.9)或手术(平均20.9,SD 12.2)的患者之间的平均决策后悔水平没有显著差异。然而,与仍接受AS治疗的患者相比,最初选择AS并转为手术的患者调整后的决策后悔水平显著更高(β系数10.1[置信区间;CI 1.3 - 18.9],P = 0.02)。在次要调整分析中,选择手术的受访者报告称,与癌症或其治疗相关的症状对生活的干扰程度比选择AS的受访者更大(P = 0.02),但在抑郁、焦虑、对疾病进展的恐惧或总体身体形象认知水平上没有显著的组间差异。在这项对小的、低风险PTC患者的研究中,与初始疾病管理选择相关的平均决策后悔水平在一年后相对较低,并且对于选择AS或手术的受访者来说没有显著差异。